Stereotactic body radiotherapy (SBRT) involves image-guided, ablative radiation delivered to cancer targets refractory to chemotherapy or to conventional radiation treatment. The robotic-armed Cyberknife SBRT system, using sophisticated target localization, delivers hypofractionated radiation doses capable of sterilizing cancer targets. This article will consider new therapeutic roles of SBRT for gynecological cancers.
Stereotactic body radiotherapy (SBRT) distinguishes itself by necessitating more rigid patient immobilization, accounting for respiratory motion, intricate treatment planning, on-board imaging, and reduced number of ablative radiation doses to cancer targets usually refractory to chemotherapy and conventional radiation. Steep SBRT radiation dose drop-off permits narrow ‘pencil beam’ treatment fields to be used for ablative radiation treatment condensed into 1 to 3 treatments.
Treating physicians must appreciate that SBRT comes at a bigger danger of normal tissue injury and chance of geographic tumor miss. Both must be tackled by immobilization of cancer targets and by high-precision treatment delivery. Cancer target immobilization has been achieved through use of indexed customized Styrofoam casts, evacuated bean bags, or body-fix molds with patient-independent abdominal compression.1-3 Intrafraction motion of cancer targets due to breathing now can be reduced by patient-responsive breath hold techniques,4 patient mouthpiece active breathing coordination,5 respiration-correlated computed tomography,6 or image-guided tracking of fiducials implanted within and around a moving tumor.7-9 The Cyberknife system (Accuray [Sunnyvale, CA]) utilizes a radiation linear accelerator mounted on a industrial robotic arm that accurately follows patient respiratory motion by a camera-tracked set of light-emitting diodes (LED) impregnated on a vest fitted to a patient.10 Substantial reductions in radiation therapy margins can be achieved by motion tracking, ultimately rendering a smaller planning target volumes that are irradiated with submillimeter accuracy.11-13
Cancer targets treated by SBRT are irradiated by converging, tightly collimated beams. Resultant radiation dose to cancer target volume histograms have a more pronounced radiation “shoulder” indicating high percentage target coverage and a small high-dose radiation “tail.” Thus, increased target conformality comes at the expense of decreased dose uniformity in the SBRT cancer target. This may have implications for both subsequent tumor control in the SBRT target and normal tissue tolerance of organs at-risk. Due to the sharp dose falloff in SBRT, the possibility of occult disease escaping ablative radiation dose occurs when cancer targets are not fully recognized and inadequate SBRT dose margins are applied. Clinical target volume (CTV) expansion by 0.5 cm, resulting in a larger planning target volume (PTV), is associated with increased target control without undue normal tissue injury.7,8 Further reduction in the probability of geographic miss may be achieved by incorporation of 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET).8 Use of 18F-FDG PET/CT in SBRT treatment planning is only the beginning of attempts to discover new imaging target molecular signatures for gynecologic cancers.
1. Stereotactic Cyberknife Radiosurgery Consultation
2. Stereotactic Cyberknife Radiosurgery Fiducial Placement
3. Stereotactic Cyberknife Radiosurgery Treatment Planning
4. Stereotactic Cyberknife Radiosurgery Treatment Delivery
5. Representative Results
Stereotactic body radiation therapy (SBRT) may involve many individual radiation beams (blue vectors) all converging on single or multiple closely associated clinical radiation targets, as shown in Figure 1A. A representative good radiosurgical planning outcome gives a deliverable SBRT treatment with high radiation dose cancer target volume coverage and cancer target conformality. Figures 1B-D show 131 beams were used to treat on a pelvic relapse of a chemorefractory ovarian cancer target over 42 minutes. SBRT prescribed to the 80% isodose line rendered 100% clinical target volume coverage with a conformality index of 1.94 for a total dose of 2400 cGy in three daily 800 cGy fractions. The dose-volume histograms for the clinical target (red) and for the critical structures of rectum (brown), bladder (yellow), small bowel (light blue) sacral nerves (tan) and hips (orange) are depicted in Figure 2.
Figure 1. Click here to view larger figure.
Figure 2. Dose-volume histograms for the clinical target (red) and for the critical structures of rectum (brown), bladder (yellow), small bowel (light blue)
sacral nerves (tan) and hips (orange).
Encouraging early SBRT outcomes have fueled clinical investigation of radiosurgery for treatment of persistent or recurrent gynecological cancers.7, 8, 15 Data question radiobiological effects and mode of cell death resulting from SBRT. Small clinical studies have shown that ablative radiation doses provided by SBRT produce targeted disease control rates exceeding 90%. Unlike with conventional radiation, it has been challenging to combine SBRT with radiosensitizing and cytotoxic/cytostatic chemotherapies. Better cancer targeting through increased planning treatment volume expansions and through inclusion of 18F-FDG PET/CT images has improved clinical outcomes. While it is imperative to look into other methods of delivering dose-escalated radiation with high precision, it remains undecided whether SBRT can provide equivalent therapeutic effectiveness as low and high dose-rate brachytherapy. Indeed, brachytherapy is the more commonly and validated technique to achieve radiation dose escalation in gynecologic cancer targets. As such, both enthusiasm and prudence are appropriate in reading available SBRT data for treatment of gynecologic cancers.
The authors have nothing to disclose.
This research was supported by the Case Comprehensive Cancer Center (P30 CA43703).
Name of the device | Company | Catalogue number | Yorumlar |
Cyberknife system | Accuray (Sunnyvale, CA) |